

Hyperalgesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/H737D6DA66D6EN.html>

Date: February 2022

Pages: 33

Price: US\$ 2,000.00 (Single User License)

ID: H737D6DA66D6EN

Abstracts

Hyperalgesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperalgesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Hyperalgesia (Central Nervous System) pipeline landscape.

Hyperalgesia is an increase in pain response. Predisposing factors include long term opioid usage, inflammation, damage to nociceptors, damage to peripheral nerves and psychological disorders. Treatment includes antidepressants and non-steroidal anti-inflammatory drugs.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperalgesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Hyperalgesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperalgesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Hyperalgesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Hyperalgesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperalgesia (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Hyperalgesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hyperalgesia (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hyperalgesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hyperalgesia (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hyperalgesia (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hyperalgesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Hyperalgesia - Overview

Hyperalgesia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hyperalgesia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hyperalgesia - Companies Involved in Therapeutics Development

Caventure Drug Discovery Inc

Charleston Laboratories Inc

Exodos Life Sciences Limited Partnership

Novartis AG

Hyperalgesia - Drug Profiles

AX-007 - Drug Profile

Product Description

Mechanism Of Action

BAM-822 - Drug Profile

Product Description

Mechanism Of Action

CAV-1001 - Drug Profile

Product Description

Mechanism Of Action

Drug for Hyperalgesia - Drug Profile

Product Description

Mechanism Of Action

ketoprofen - Drug Profile

Product Description

Mechanism Of Action

mol-002291 - Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibody to Inhibit TGF-Beta-1 for Chronic Pancreatitis Pain and
Hyperalgesia - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Antagonize GPR4 for Arthritis, Hyperalgesia and Oncology - Drug
Profile

Product Description

Mechanism Of Action

ZH-853 - Drug Profile

Product Description

Mechanism Of Action

Hyperalgesia - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Hyperalgesia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hyperalgesia - Pipeline by Caventure Drug Discovery Inc, 2022
Hyperalgesia - Pipeline by Charleston Laboratories Inc, 2022
Hyperalgesia - Pipeline by Exodos Life Sciences Limited Partnership, 2022
Hyperalgesia - Pipeline by Novartis AG, 2022
Hyperalgesia - Dormant Projects, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hyperalgesia, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Routes of Administration, 2022

I would like to order

Product name: Hyperalgesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/H737D6DA66D6EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H737D6DA66D6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

